趋化因子CCR5，作为G蛋白偶联因子超家族(GPCR)成员的细胞膜蛋白，是HIV-1入侵机体细胞的主要辅助受体之一。以CCR5为靶点的HIV-1受体拮抗剂越来越受关注，主要有趋化因子衍生物、非肽类小分子化合物、单克隆抗体、肽类化合物等四类。这些抗病毒活性强、高亲和力的CCR5拮抗剂,已有一部分进入了临床试验阶段。本文对近年来CCR5拮抗剂的相关研究进展进行综述。
Chemokine receptor 5 (CCR5 ),as a member of the G protein-coupled receptor （GPCR）superfamily，is a membrane protein on cell surface and one of the major of coreceptors for HIV-1infection.CCR5 has became a molecular target for the novel drugs against HIV-1,and Antagonists for CCR5 could be grouped as following, chemokine derivatives,small molecule non-peptide compounds,molecular antibodies and peptides. These compounds with high anti-viral activity and affinity are at different stages, and some have been under clinical studies.This review is about the development research in the different kind of CCR5 antagonists.
国家自然科学基金;其它项目基金
吴英萍,吴文言. CCR5及其拮抗剂的研究进展[J]. 中国生物工程杂志, 2008, 28(11): 89-96.
https://manu60.magtech.com.cn/biotech/CN/Y2008/V28/I11/89
Cited
